| Pharmaceutical active ingredients: |
| Coagulation Factor VIII Human |
| Available forms, composition and doses of Monarc-M: |
| Injectable; Injection; 1,000 IUInjectable; Injection; 500 IU |
| Monarc-M medical category: |
| Human:Hemostatics |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| B02BD02 - Coagulation Factor VIII |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| BaxterAmerican Red CrossKamadaTeva |
| Related documents and information about Monarc-M: |
| Monarc-M prescribing information (PDF) |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Fanhdi | Coagulation Factor VIII Human | Grifols; Demo; ProMedico |
| Haemate-P | Coagulation Factor VIII Human | CSL |
| Hemofil M | Coagulation Factor VIII Human | Baxter; Bioscience; Firma Chun Cheong; Teva; United Italian Trading |
| Koate D-IV | Coagulation Factor VIII Human | Bayer Schering Pharma |
| Koate-DVI | Coagulation Factor VIII Human | Bayer Schering Pharma; Dipa Pharmalab Intersains; Gador; GenAsia Biotech; Luen Cheong Hong; Octafarma; Talecris; Talecris Biotherapeutics; Zuellig Pharma |
| Monoclate-P | Coagulation Factor VIII Human | Sanofi-Aventis; Gerolymatos; Medibrands; Rephachem; ZLB Behring; Zydus Cadila |
| Octanate | Coagulation Factor VIII Human | Octapharma; B L Hua; Bago Laboratorios; Varifarma Laboratorio |
| Recombinate | Coagulation Factor VIII Human | Baxter; Teva |
| Wilstart | Coagulation Factor VIII Human; Von Willebrand Factor Human | LFB Biomedicaments |
| Feiba | Coagulation Factor VIII Inhibitor Bypassing Fraction | Baxter; Immuno Productos Biologicos e Quimicos; Teva |